Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin
Authors: Mei Qiu
Journal: Annals of Internal Medicine (2022)

LettersDecember 2022Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus MetforminMei Qiu, MSMei Qiu, MSCenter of Community Health Service Management, Shenzhen Longhua District Central Hospital, Shenzhen City, ChinaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0332 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Shin and colleagues carried out a cohort study (1) and drew the key conclusion that use of first-line treatment with sodium–glucose cotransporter-2 inhibitors (SGLT-2i) versus metformin significantly decreased hospitalization for heart failure (HHF) and the composite outcome of HHF or all-cause mortality (HHF/mortality) in patients with type 2 diabetes (T2D). Although the authors conducted subgroup analyses stratified by history of cardiovascular disease (CVD), they did not mention any content related to subgroup analyses in the conclusion of their article. I am interested in the results of subgroup analyses on heart failure–associated outcomes.As shown in Figure 4 ...References1. Shin H, Schneeweiss S, Glynn RJ, et al. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium–glucose cotransporter-2 inhibitors versus metformin. A cohort study. Ann Intern Med. 2022;175:927-37. [PMID: 35605236] doi:10.7326/M21-4012 LinkGoogle Scholar2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-9. [PMID: 30424892] doi:10.1016/S0140-6736(18)32590-X CrossrefMedlineGoogle Scholar3. Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908. [PMID: 31992158] doi:10.1161/JAHA.119.014908 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Center of Community Health Service Management, Shenzhen Longhua District Central Hospital, Shenzhen City, ChinaDisclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L22-0332. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin HoJin Shin , Sebastian Schneeweiss , Robert J. Glynn , and Elisabetta Patorno Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin HoJin Shin , Sebastian Schneeweiss , Robert J. Glynn , and Elisabetta Patorno Metrics December 2022Volume 175, Issue 12Page: W155KeywordsCardiovascular diseasesDiabetes medicationsMortalityType 2 diabetes ePublished: 20 December 2022 Issue Published: December 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...